LIFEPHARMS, INC.

Company Information

Company Name
LIFEPHARMS, INC.
Address
143 Shaw Street
New London, CT, 06320-
Phone
n/a
URL
n/a
DUNS
172904067
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
Y
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$2,189,708.00
7
SBIR Phase II
$904,482.00
1
Chart code to be here

Award List

  1. Discovery of novel agents against M. tuberculosis.

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): Despite the fact that tuberculosis is a major public global health problem, there have been no drugs developed for it since the 1960s. In 2006 tuberculosis caused ...

    SBIR Phase I 2010 Department of Health and Human Services
  2. Nucleoside hydrolase Inhibitors from natural products for Leishmania

    Amount: $211,698.00

    DESCRIPTION (provided by applicant): Our goal is to identify novel drugs for the treatment and chemoprophylaxis of Leishmania by blocking nucleoside hydrolase (NH) activity of this parasite. Leishmani ...

    SBIR Phase I 2010 Department of Health and Human Services
  3. Discovery of cell cycle inhibitors from natural products

    Amount: $904,482.00

    DESCRIPTION (provided by applicant): The need for new and effective chemotherapeutic agents that selectively target cancer cells and thus, would have a much higher therapeutic index is urgent. Most c ...

    SBIR Phase II 2005 Department of Health and Human Services
  4. POTENTIAL ANTICANCER AGENTS FROM BASIDIOMYCETES

    Amount: $100,000.00

    LifePharms, Inc. has established a collection of >12,000 unique species of basidiomycetes/ascomycetes, and the Natural Products Laboratory of Research Triangle Institute has a long and successful hist ...

    SBIR Phase I 2001 Department of Health and Human Services
  5. Discovery of novel antibacterials from a mushroom natural product library

    Amount: $378,012.00

    DESCRIPTION (provided by applicant): The dramatic increase in the prevalence of antibiotic resistance among important hospital- and community-acquired bacterial pathogens poses a serious threat to our ...

    SBIR Phase I 2009 Department of Health and Human Services
  6. Novel Antibacterial Scaffold from Natural Products

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Despite the rise of bacterial resistance to antibiotics, the development of new antibiotics is on the decline. Methicillin-resistant Staphococcal aureus infections ...

    SBIR Phase I 2011 Department of Health and Human Services
  7. Novel antifungals for Immunocompromised/HIV patients.

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): Fungal infections continue to be a major cause of morbidity and mortality among HIV- infected patients. At present, there are only three classes of antifungal age ...

    SBIR Phase I 2011 Department of Health and Human Services
  8. Hsp90 inhibitors to combat antifungal drug resistance.

    Amount: $299,998.00

    DESCRIPTION (provided by applicant): Fungal infections continue to be a major cause of morbidity and mortality among HIV-infected patients. Many of the emerging fungal pathogens that are resistant to ...

    SBIR Phase I 2012 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government